SCHEMBL9719340

SCHEMBL9719340

O=C1C(Cc2cccnc2)c2ccccc2N1c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.51
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALOX5 P09917 3/20 0.42
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
CES2 O00748 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.39
CYP2C19 P33261 1/20 0.39
CACNA1G O43497 1/20 0.39
CACNA1H O95180 1/20 0.39
CACNA1I Q9P0X4 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
OPRL1 P41146 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4599210 0.85 ALDH1A1 (0.48) LMNAALOX5CES2CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL8805740 0.84 MAPK1 (0.48) LMNAALOX5CES2CYP1A2CYP3A4
SCHEMBL8806746 0.81 L3MBTL1 (0.39) LMNAL3MBTL1ALOX5CYP1A2CYP3A4
SCHEMBL29158505 0.77 ALDH1A1 (0.55) LMNAALOX5CES2CYP1A2CYP3A4
SCHEMBL9719389 0.76 LMNA (0.44) LMNAALOX5CYP1A2CYP3A4GAA
SCHEMBL8805922 0.76 LMNA (0.39) LMNAL3MBTL1ALOX5CYP1A2CYP3A4
SCHEMBL4687956 0.75 ALOX5 (0.50) ALOX5CES2CYP1A2CYP3A4GAA
SCHEMBL9719342 0.74 ALOX5 (0.47) LMNAL3MBTL1ALOX5CYP11B1CYP11B2
SCHEMBL12203852 0.73 OPRM1 (0.46) ALOX5CES2GAAOPRM1OPRK1
SCHEMBL27632123 0.72 L3MBTL1 (0.46) LMNAL3MBTL1GAAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1992000760-A1 METHOD OF TREATING NEUROLOGICAL DYSFUNCTION USING NEUROTRANSMITTER ENHANCES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-01-23 WO disclosed